RYE, N.Y., Dec. 2, 2010 /PRNewswire/ — Curemark, LLC,
(www.curemark.com), a drug
research and development company focused on the treatment of
neurological diseases, announced that four additional sites across
the country are now participating in Phase III clinical trials for
the company’s autism treatment CM-AT. The new trial
sites are:
- Institute for Behavioral Medicine, Smyrna, Georgia
- Cyn3rgy Research, Gresham, Oregon
- Westside Medical Clinic, Clinton, Utah
- Oklahoma University Physician’s Child Study Center, Oklahoma
City
There are now a total of 19 sites nationally conducting Phase
III trials for Curemark’s autism therapy. The study is
targeting a total enrollment of 170 children.
“We have been extremely pleased with the response and the level
of participation in the CM-AT autism study,” said Dr. Joan Fallon,
Curemark founder and CEO. “Enrollment is continuing to
proceed well at our other trial sites throughout the country.”
CM-AT, which has received Fast Track status from the FDA,
targets enzyme deficiencies in autistic children, resulting in an
inability to digest protein. The inability to digest protein
affects the availability of amino acids, the building blocks of
chemicals essential for brain function. If approved, CM-AT
will be one of the first therapies to address the underlying
physiology of autism.
For information on enrolling in the Curemark CM-AT autism
trials, log on to www.clinicaltrials.gov
and search “Curemark.”
About CUREMARK LLC
Curemark is a drug research and development company focused on
the treatment of neurological and other diseases, especially those
with dysautonomic components, by addressing certain key
gastrointest
‘/>”/>
